Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
José C. Jaime-Pérez, Marcela Hernández-Coronado, Ernesto Picón-Galindo, Lorena Salazar-Cavazos, César Homero Gutiérrez-Aguirre & David Gómez-Almaguer. (2021) Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning. Leukemia & Lymphoma 62:7, pages 1619-1628.
Read now
Read now
Theodoros Karantanos, Ioannis Politikos & Vassiliki A Boussiotis. (2017) Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies. Blood and Lymphatic Cancer: Targets and Therapy 7, pages 37-52.
Read now
Read now
Massimo Martino, Anna Grazia Recchia, Giuseppe Console, Massimo Gentile, Michele Cimminiello, Giuseppe Alberto Gallo, Anna Ferreri, Virginia Naso, Giuseppe Irrera, Giuseppe Messina, Tiziana Moscato, Ernesto Vigna, Iolanda Donatella Vincelli & Fortunato Morabito. (2017) Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?. Expert Opinion on Orphan Drugs 5:11, pages 875-887.
Read now
Read now
Danielle H. Oh, Neil Chua, Lesley Street & Douglas A. Stewart. (2016) Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leukemia & Lymphoma 57:1, pages 28-33.
Read now
Read now
Ioanna Sakellari, Despoina Mallouri, Ioannis Batsis, Chrysa Apostolou, Varnavas Konstantinou, Eleni-Maria Abela, Vasiliki Douka, Anastasia Marvaki, Kyriakos Karypidis, Michalis Iskas, Panayiotis Baliakas, Panayotis Kaloyannidis, Evangelia Yannaki, Damianos Sotiropoulos, Giorgos Kouvatseas, Christos Smias & Achilles Anagnostopoulos. (2015) Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Leukemia & Lymphoma 56:11, pages 3071-3081.
Read now
Read now
Gregory MT Guilcher & Douglas A Stewart. (2014) Relapsed Hodgkin lymphoma in adolescents: focus on current high-dose chemotherapy and autologous stem cell transplant. Clinical Oncology in Adolescents and Young Adults 4, pages 1-12.
Read now
Read now
Satyajit Kosuri & Koen van Besien. (2014) Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. Leukemia & Lymphoma 55:3, pages 476-477.
Read now
Read now
Articles from other publishers (12)
Ryan C. Schofield, Michael Scordo, Gunjan Shah & Dean C. Carlow. 2024. Clinical Applications of Mass Spectrometry in Drug Analysis. Clinical Applications of Mass Spectrometry in Drug Analysis
423
433
.
E Joffe, D Rosenberg, U Rozovski, C Perry, I Kirgner, S Trestman, O Gur, F Aviv, N Sarid, A Kolomansky, L Gepstein, Y Herishanu & E Naparstek. (2017) Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma. Bone Marrow Transplantation 53:1, pages 29-33.
Crossref
Crossref
G Damaj, J Cornillon, K Bouabdallah, R Gressin, S Vigouroux, T Gastinne, F Ranchon, H Ghésquières, G Salles, I Yakoub-Agha & E Gyan. (2017) Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Bone Marrow Transplantation 52:7, pages 941-949.
Crossref
Crossref
. 2017. Hematopoietic Cell Transplants. Hematopoietic Cell Transplants
361
444
.
Stefanie Gilli, Urban Novak, Behrouz Mansouri Taleghani, Gabriela M. Baerlocher, Kurt Leibundgut, Yara Banz, Thilo Zander, Daniel Betticher, Thomas Egger, Daniel Rauch & Thomas Pabst. (2016) BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Annals of Hematology 96:3, pages 421-429.
Crossref
Crossref
Christopher R. Flowers, Luciano J. Costa, Marcelo C. Pasquini, Jennifer Le-Rademacher, Michael Lill, Tsiporah B. Shore, William Vaughan, Michael Craig, Cesar O. Freytes, Thomas C. Shea, Mitchell E. Horwitz, Joseph W. Fay, Shin Mineishi, Damiano Rondelli, James Mason, Ira Braunschweig, Weiyun Ai, Rosa F. Yeh, Tulio E. Rodriguez, Ian Flinn, Terrance Comeau, Andrew M. Yeager, Michael A. Pulsipher, Isabelle Bence-Bruckler, Pierre Laneuville, Philip Bierman, Andy I. Chen, Kazunobu Kato, Yanlin Wang, Cong Xu, Angela J. Smith & Edmund K. Waller. (2016) Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation 22:7, pages 1197-1205.
Crossref
Crossref
Andrew J. Cowan, Philip A. Stevenson, Ryan D. Cassaday, Solomon A. Graf, Jonathan R. Fromm, David Wu, Leona A. Holmberg, Brian G. Till, Thomas R. Chauncey, Stephen D. Smith, Mary Philip, Johnnie J. Orozco, Andrei R. Shustov, Damian J. Green, Edward N. LibbyIIIIII, William I. Bensinger, Mazyar Shadman, David G. Maloney, Oliver W. Press & Ajay K. Gopal. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biology of Blood and Marrow Transplantation 22:2, pages 380-385.
Crossref
Crossref
Maurizio Musso, Giuseppe Messina, Nicola Di Renzo, Paolo Di Carlo, Umberto Vitolo, Renato Scalone, Gianpaolo Marcacci, Potito R. Scalzulli, Tiziana Moscato, Rossella Matera, Alessandra Crescimanno, Stella Santarone, Enrico Orciuolo, Anxur Merenda, Vincenzo Pavone, Domenico Pastore, Daniela Donnarumma, Angelo M. Carella, Chiara Ciochetto, Nicola Cascavilla, Anna Mele, Francesco Lanza, Massimo Di Nicola, Erminio Bonizzoni & Antonello Pinto. (2015) Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen. British Journal of Haematology 172:1, pages 111-121.
Crossref
Crossref
Maurizio Musso, Giuseppe Messina, Gianpaolo Marcacci, Alessandra Crescimanno, Giuseppe Console, Daniela Donnarumma, Renato Scalone, Antonio Pinto & Massimo Martino. (2015) High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study. Biology of Blood and Marrow Transplantation 21:11, pages 1932-1938.
Crossref
Crossref
Miguel-Angel Perales, Izaskun Ceberio, Philippe Armand, Linda J. Burns, Robert Chen, Peter D. Cole, Andrew M. Evens, Ginna G. Laport, Craig H. Moskowitz, Uday Popat, Nishitha M. Reddy, Thomas C. Shea, Julie M. Vose, Jeffrey Schriber, Bipin N. Savani & Paul A. Carpenter. (2015) Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 21:6, pages 971-983.
Crossref
Crossref
Yi-Bin Chen, Andrew A. Lane, Brent R. Logan, Xiaochun Zhu, Görgün Akpek, Mahmoud D. Aljurf, Andrew S. Artz, Christopher N. Bredeson, Kenneth R. Cooke, Vincent T. Ho, Hillard M. Lazarus, Richard F. Olsson, Wael Saber, Philip L. McCarthy & Marcelo C. Pasquini. (2015) Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 21:6, pages 1046-1053.
Crossref
Crossref
Mark Hertzberg. (2014) Relapsed/Refractory Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:1, pages 123-147.
Crossref
Crossref